Vizgen is at the forefront of spatial biology and multi-omics innovation. Through its pioneering MERFISH technology and MERSCOPE® Platform for in situ single-cell spatial genomics and its high-fidelity InSituPlex® assays and AI-driven STARVUE™ spatial image analysis technology, Vizgen delivers unmatched tools that enable researchers to uncover deep insights into human biology and achieve breakthroughs in understanding mechanisms of complex diseases. Vizgen’s technology delivers high-confidence, quantitative data with exceptional accuracy, robustness, sensitivity and deep insights that power foundational and clinical research.

Joined Ultivue as CEO in May 2023 and merged it with Vizgen in October 2024.Ultivue provides researchers with the clearest profile of cancer biology, enabling them to see more, to see faster, and to see in situ. Through ultra-sensitive InSituPlex® assays and advanced AI-driven spatial analysis, Ultivue empowers scientists developing precision cancer therapies to generate quantitative, high confidence insights in just a fraction of the time.

Immune repertoire profiling for your next therapeutic breakthrough

Provide strategy consulting to privately-held life sciences companies and their institutional investors. Evaluated private M&A opportunities.

Pioneering the detection of early cancer

ALDA (Analytical, Life Science & Diagnostics Association) is a non-profit industry trade association for global companies that develop and market products and services used in life science research, drug discovery, QA/QC and food testing, and clinical and molecular diagnostics.

RedShiftBio has developed a proprietary life sciences platform combining its Microfluidic Modulation Spectroscopy (MMS) and expertise in high powered quantum cascade lasers that provides ultra-sensitive and ultra-precise measurements of molecular structure. These structural changes affect critical quality attributes governing the safety, efficacy, and stability of biomolecules and their raw materials.

Built and led strategy, transformation (commercial and R&D-focused), M&A, venture investment and communications teams for a then-$2.4B, 7400-employee company that is an innovator in instrumentation and software used for the analysis of biopharmaceuticals, advanced materials, patient samples (clinical diagnostics) and food/environmental samples.

This Waters business unit enables development of higher performing, safer battery products for cars, medical devices, and everything in between with industry-leading material analysis.

Owned P&L for Medtronic’s $1.4 billion pacemaker business unit, part of its Cardiac Rhythm & Heart Failure segment. Team revolutionized a 60-year old industry, using miniaturized battery, sensor and wireless transmission technologies. With these it brought the benefits of minimally-invasive therapy and greater engagement to patients around the world, fueling the growth of Medtronic’s foundational business.

Outpatient & Value-Based Care Solutions (Spine)

Pan-Medtronic body of GMs and senior marketing and sales leaders focused on commercial capability development

Global Marketing & Strategy (Spine & Biologics Business)

Therapy Segment LeaderThoracolumbar Therapies

Therapy Segment LeaderComplex Spine & Orthopaedics (Biologics)

Complex Spine & Orthopaedics (Biologics)

Completed transactions include underwriting of commercial mortgage-backed securities for The Westin St. Francis Hotel (San Francisco).